EQ

EquilliumD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$2.60

-6.8% vs current

Most likely

Base case

45%

Probability

Target price

$1.40

-49.8% vs current

B-

Bear case

30%

Probability

Target price

$0.80

-71.3% vs current

AI sentiment snapshot

Latest data as of 2026-04-15

AI commentary

Sentiment looks cautious rather than bullish: March financing and runway support reduced near-term distress risk, but there is no recent operating news beyond the March 25, 2026 filing package, partnership revenue from Ono has ended, and investors still need EQ504 clinical execution to justify upside [#10-K-2026-03-25] [#8-K-2026-03-25].

RankAlpha Sentiment Codex - 2026-04-15

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-07-15eventEQ504 Phase 1 proof-of-mechanism study start is targeted for mid-2026High impact

Equillium says it has completed preclinical work for EQ504 and plans to initiate a Phase 1 proof-of-mechanism study in mid-2026, making first-in-human execution the clearest near-term re-rating trigger for the story [#10-K-2026-03-25] [#8-K-2026-03-25].

2026-12-31catalystCash runway improved, but milestone-linked financing terms still leave dilution and execution as core gating itemsHigh impact

Equillium reported $30.3 million of cash and short-term investments at year-end 2025 and says the March 2026 financing supports operations into 2029, while the August 2025 deal still includes a potential second closing of up to $20 million only if EQ504 development and share-price conditions are met or waived [#10-K-2026-03-25] [#8-K-2026-03-25].

2027-01-15eventInitial EQ504 data could arrive roughly six months after study startHigh impact

The company disclosed that data are expected approximately six months after the planned mid-2026 Phase 1 initiation, so any slippage or weak proof-of-mechanism signals would likely matter more than routine financial updates for a single-lead-asset setup [#8-K-2026-03-25] [#10-K-2026-03-25].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-15 • Updated nightlySource: Internal modelMethodology